Most Read Articles
Christina Lau, 02 Jan 2020

Tolvaptan improves dyspnoea, increases sodium levels and reduces body weight in patients with acute heart failure (HF) with or without hyponatraemia, but no significant effect is seen in mortality or rehospitalization, according to a recent meta-analysis.

Pearl Toh, 15 Apr 2020
Transcatheter aortic valve replacement (TAVR) in patients with bicuspid aortic stenosis who are at low surgical risk appears to be safe with low rates of death or disabling stroke at 30 days, according to a study presented at the ACC.20/WCC Virtual Meeting.

A Summary of the Malaysian Hypertension Clinical Practice Guidelines

24 Sep 2019
Hypertension (HPT) is defined as a persistent elevation of systolic blood pressure (BP) of 140 mmHg or greater and/or diastolic BP of 90 mmHg or greater, taken at least twice ontwo separate occasions. The most recent National Health and Morbidity Survey (NHMS) 2015 that focuses on noncommunicable diseases showed that among adults aged 18 years and older, there was an increase in the prevalence of HPT from 33.6% in 2011 to 35.3%. While the proportion of patients with HPT who have attained good BP control has increased from 34.7% in 2011 to 37.4%, the awareness of the condition among patients remains poor. The prevalence of undiagnosed HPT remains high; hence, it is recommended that every adult aged 18 years and older to check their BP at least once annually, and more frequently in those with risk factors (eg, family history, obese).
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 02 Jan 2020

Tolvaptan improves dyspnoea, increases sodium levels and reduces body weight in patients with acute heart failure (HF) with or without hyponatraemia, but no significant effect is seen in mortality or rehospitalization, according to a recent meta-analysis.

Pearl Toh, 15 Apr 2020
Transcatheter aortic valve replacement (TAVR) in patients with bicuspid aortic stenosis who are at low surgical risk appears to be safe with low rates of death or disabling stroke at 30 days, according to a study presented at the ACC.20/WCC Virtual Meeting.